{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:18:34Z","timestamp":1780690714243,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.arcmed.2020.09.010","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T16:31:27Z","timestamp":1599755487000},"page":"15-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development"],"prefix":"10.1016","volume":"52","author":[{"given":"Kevin","family":"Ita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2020.09.010_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajog.2020.03.021","article-title":"Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy","volume":"222","author":"Dashraath","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.arcmed.2020.09.010_bib2","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.arcmed.2020.09.010_bib3","doi-asserted-by":"crossref","first-page":"v","DOI":"10.1016\/j.vaccine.2020.02.039","article-title":"Another coronavirus, another epidemic, another warning","volume":"38","author":"Poland","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2020.09.010_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Adnan Shereen","year":"2020","journal-title":"J Adv Res"},{"key":"10.1016\/j.arcmed.2020.09.010_bib5","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.arcmed.2020.09.010_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/tmi.13383","article-title":"The COVID-19 epidemic","volume":"25","author":"Velavan","year":"2020","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.arcmed.2020.09.010_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.arcmed.2020.09.010_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.micinf.2020.03.003","article-title":"Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2","volume":"22","author":"Qiu","year":"2020","journal-title":"Microbes Infect"},{"key":"10.1016\/j.arcmed.2020.09.010_bib9","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"10.1016\/j.arcmed.2020.09.010_bib10","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.09.010_bib12","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1016\/j.vaccine.2020.04.070","article-title":"The biological characteristics of SARS-CoV-2 Spike protein Pro330-Leu650","volume":"38","author":"Su","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2020.09.010_bib13","doi-asserted-by":"crossref","first-page":"104327","DOI":"10.1016\/j.meegid.2020.104327","article-title":"Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status","volume":"83","author":"Abd El-Aziz","year":"2020","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.arcmed.2020.09.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2020.05.021","article-title":"Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines","author":"Shih","year":"2020","journal-title":"Biomed J"},{"key":"10.1016\/j.arcmed.2020.09.010_bib15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.chempr.2020.04.023","article-title":"Chemistry and Biology of SARS-CoV-2","volume":"6","author":"D\u00f6mling","year":"2020","journal-title":"Chem"},{"key":"10.1016\/j.arcmed.2020.09.010_bib16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2020.09.010_bib17","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.arcmed.2020.09.010_bib18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacbts.2020.04.002","article-title":"COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies","volume":"5","author":"Atri","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.arcmed.2020.09.010_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Vanessa Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.arcmed.2020.09.010_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/21645515.2020.1735227","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","volume":"16","author":"Dhama","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.arcmed.2020.09.010_bib21","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","volume":"55","author":"Zhai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.09.010_bib22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: the reality and challenges","volume":"53","author":"Jean","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.arcmed.2020.09.010_bib23","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.09.010_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jaccas.2020.04.001","article-title":"The Imperfect Cytokine Storm: Severe COVID-19 with ARDS in Patient on Durable LVAD Support","volume":"2","author":"Chau","year":"2020","journal-title":"JACC Case Rep"},{"issue":"6491","key":"10.1016\/j.arcmed.2020.09.010_bib25","first-page":"630","article-title":"A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.arcmed.2020.09.010_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.arcmed.2020.09.010_bib27","doi-asserted-by":"crossref","first-page":"101647","DOI":"10.1016\/j.tmaid.2020.101647","article-title":"Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence","volume":"35","author":"Cao","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.arcmed.2020.09.010_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25761","article-title":"The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase","author":"Lung","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.arcmed.2020.09.010_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol. Nat Biotechnol"},{"key":"10.1016\/j.arcmed.2020.09.010_bib30","first-page":"2352","article-title":"Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic","volume":"75","author":"Driggin","year":"2020"},{"key":"10.1016\/j.arcmed.2020.09.010_bib31","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arcmed.2020.09.010_bib32","doi-asserted-by":"crossref","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.arcmed.2020.09.010_bib33","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2020.09.010_bib34","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.arcmed.2020.09.010_bib35","doi-asserted-by":"crossref","first-page":"104859","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.arcmed.2020.09.010_bib36","doi-asserted-by":"crossref","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arcmed.2020.09.010_bib37","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.09.010_bib38","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.09.010_bib39","doi-asserted-by":"crossref","first-page":"117883","DOI":"10.1016\/j.lfs.2020.117883","article-title":"Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements","volume":"256","author":"Pandey","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.arcmed.2020.09.010_bib40","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in\u00a0vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arcmed.2020.09.010_bib41","first-page":"43","article-title":"Vaccines for COVID-19: the current state of play","volume":"35","author":"Koirala","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.arcmed.2020.09.010_bib42","doi-asserted-by":"crossref","first-page":"105375","DOI":"10.1016\/j.ejps.2020.105375","article-title":"High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19","volume":"151","author":"Ojha","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.arcmed.2020.09.010_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-020-0170-0","article-title":"The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines","volume":"5","author":"Shang","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.arcmed.2020.09.010_bib44","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.biopha.2017.07.019","article-title":"Dissolving microneedles for transdermal drug delivery: Advances and challenges","volume":"93","author":"Ita","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.arcmed.2020.09.010_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/pharmaceutics7030090","article-title":"Transdermal Delivery of Drugs with Microneedles-Potential and Challenges","volume":"7","author":"Ita","year":"2015","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arcmed.2020.09.010_bib46","first-page":"2683286","article-title":"Design of multi epitope-based peptide vaccine against E protein of human COVID-19: An immunoinformatics approach","volume":"2020","author":"Abdelmageed","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.arcmed.2020.09.010_bib47","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.medidd.2020.100026","article-title":"Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus","volume":"5","author":"Ji","year":"2020","journal-title":"Med Drug Discov"},{"key":"10.1016\/j.arcmed.2020.09.010_bib50","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.vaccine.2019.11.083","article-title":"Enhancing the immunogenicity of a DNA vaccine against Streptococcus mutans by attenuating the inhibition of endogenous miR-9","volume":"38","author":"Jia","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2020.09.010_bib51","article-title":"DNA immunization as an efficient strategy for vaccination","author":"Bolhassani","year":"2009","journal-title":"Avicenna J Med Biotechnol"},{"key":"10.1016\/j.arcmed.2020.09.010_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2019.05.008","article-title":"A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development","volume":"268","author":"Luo","year":"2019","journal-title":"Virus Res"},{"key":"10.1016\/j.arcmed.2020.09.010_bib54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","article-title":"Enzymatic assembly of DNA molecules up to several hundred kilobases","volume":"6","author":"Gibson","year":"2009","journal-title":"Nat Methods"},{"key":"10.1016\/j.arcmed.2020.09.010_bib55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.arcmed.2020.09.010_bib56","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2020.09.010_bib57","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2020.09.010_bib59","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.arcmed.2020.09.010_bib60","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2020.09.010_bib61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jmv.25698","article-title":"Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV","volume":"92","author":"Baruah","year":"2020","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.arcmed.2020.09.010_bib62","doi-asserted-by":"crossref","first-page":"E254","DOI":"10.3390\/v12030254","article-title":"Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.arcmed.2020.09.010_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25736","article-title":"Development of epitope-based peptide vaccine against novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics approach","author":"Bhattacharya","year":"2020","journal-title":"J Med Virol"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920311541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920311541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:49:54Z","timestamp":1759261794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440920311541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0188440920311541"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.09.010","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}